

IN THE CLAIMS:

1. (Previously Presented) A vaccine composition containing proteolipidic cochlear structures obtained from outer membrane vesicles of live microorganisms selected from the group consisting of bacterial, protozoan or animal cell organism and additionally contain one or more antigens.
2. (Previously Presented) The vaccine composition according to claim 1, with said cochlear structures comprised of proteins, lipids and pathogen associated molecular pattern.
3. (Previously Presented) The vaccine composition according to claim 2, with said pathogen associated molecular pattern added at a concentration between 1% and 30% of the protein weight of the cochlear structure.
4. (Previously Presented) The vaccine composition according to claim 3, with said pathogen associated molecular pattern being selected from the group consisting of lipopolysaccharides, peptidoglycan, lipoprotein, teicoic acid, flagellin and lipophosphoglycane.
5. (Cancelled)

6. (Previously Presented) The vaccine composition according to claim 1, characterized by the fact that said bacterium is one of Gram negative or Gram positive.

7. (Previously Presented) The vaccine composition according to claim 6, characterized by the fact that said Gram negative bacterium comprises one of the, *Neisseria*, *Haemophilus*, *Salmonella*, *Vibrio*, *Pseudomona* or *Shigella* genus.

8. (Previously Presented) The vaccine composition according to claim 6, characterized by the fact that said Gram positive bacterium may be of the *Streptococcus* or *Staphylococcus* genus.

9. (Currently Amended) The vaccine composition according to claim 1, characterized by the fact that said live organism is the protozoan of the *Leishmania* *Leishmania* genus.

10. (Previously Presented) The vaccine composition according to claim 1, characterized by the fact that the cochlear structures are extracted from a tumor cell.

11. (Previously Presented) The vaccine composition according to claim 1, wherein the antigens are in a ratio with the proteins present in the cochlear structure of 0.2 to 2.7  $\mu$ g to 3 to 9  $\mu$ g of protein.

12. (Previously Presented) The vaccine composition according to claim 1, wherein the antigens are selected from the group consisting of natural or recombining proteins, peptides, saccharides, nucleic acids, conjugates or allergens.

13. (Previously Presented) The vaccine composition according to claim 12, wherein the antigen is a protein from the hepatitis C virus.

14. (Previously Presented) The vaccine composition according to claim 12, wherein the antigen is the recombining protein P1 from papillomavirus.

15. (Previously Presented) The vaccine composition according to claim 12, wherein the antigen is the epitope T or B.

16. (Previously Presented) The vaccine adjuvant comprising proteolipidic cochlear structures obtained from vesicles found in the outer membranes of live organisms selected from the group consisting of bacterium, protozoan or an animal cell.

17. (Previously Presented) The vaccine adjuvant according to claim 16, wherein said cochlear structures comprise proteins, lipids, and pathogens associated molecular pattern .

18. (Previously Presented) The vaccine adjuvant according to claim 17, wherein said pathogens associated molecular pattern are found at a concentration between 1% and 30 % of the protein weight of the structure.

19. (Previously Presented) The vaccine adjuvant according to claim 17, wherein said pathogen associated molecular pattern are selected from the group consisting of lipopolysaccharide, peptyglycane, lipoprotein, teicoic acid, flagellin and lipophosphoglycane.

20. (Cancelled)

21. (Previously Presented) The vaccine adjuvant according to claim 16, wherein said bacterium is a Gram negative or a Gram positive.

22. (Previously Presented) The vaccine adjuvant according to claim 21, wherein said Gram negative bacterium is one of *Neisseria*, *Haemophilus*, *Salmonella*, *Vibrio*, *Pseudomona* or *Shigella* genus.

23. (Previously Presented) The vaccine adjuvant according to claim 21, wherein said Gram positive bacterium is one of the *Streptococcus* or *Staphylococcus* genus.
24. (Previously Presented) The vaccine adjuvant according to claim 16, characterized by the fact that said live organism is a protozoan organism from the *Leishmania* genus.
25. (Previously Presented) The vaccine adjuvant according to claim 16, said cochlear structures comprise a tumor cell cochlear structures.
26. (Previously Presented) A vaccine composition containing vesicles obtained from the outer membrane of live organisms selected from the group consisting of bacterium, protozoan or an animal cell.
27. (Previously Presented) The vaccine composition according to claim 26, said outer membrane vesicles comprising proteins, lipids and molecular pathogen associated molecular pattern .
28. (Previously Presented) The vaccine composition according to claim 27, said pathogen associated molecular pattern are in a concentration of between 1% and 7% of the protein weight of the structure.

29. (Previously Presented) The vaccine composition according to claim 27, said pathogen associated molecular pattern selected from the group consisting of lipopolysaccharide, peptidoglycon, teicoic acid, flagellin and lipophosphoglycane.

30. (Cancelled)

31. (Previously Presented) The vaccine composition according to claim 26, said bacterium is a Gram negative or a Gram positive.

32. (Previously Presented) The vaccine composition according to claim 31, said Gram negative bacterium is one of *Neisseria* , *Haemophilus* , *Salmonella*, *Vibrio* , *Pseudomona* or *Shigella* genus.

33. (Previously Presented) The vaccine composition according to claim 31, characterized by the fact that said Gram positive bacterium is one of the *Streptococcus* or *Staphylococcus* genus.

34. (Previously Presented) The vaccine composition according to claim 26, said live organism is a protozoan organism from the *Leishmania* genus.

35. (Previously Presented) The vaccine composition according to claim 26, with the outer membrane vesicles comprise a tumor cell vesicles.

36. (Previously Presented) The vaccine adjuvant containing vesicles extracted from the outer membrane of live organisms selected from the group consisting of bacterium, protozoan or an animal cell.

37. (Previously Presented) The vaccine adjuvant according to claim 36 said outer membrane vesicles comprising proteins, lipids, and molecular structures associated to pathogens.

38. (Previously Presented) The vaccine adjuvant according to claim 37, with said molecular structures associated to pathogens are in a concentration between 1% and 7% of the protein weight of the structure.

39. (Previously Presented) The vaccine adjuvant according to claim 37, said pathogens associated molecular pattern being selected from the group consisting of lipopolysaccharide, peptidoglycan, teicoic acid, flagellin and lipophosphoglycane.

40. (Cancelled)

41. (Previously Presented) The vaccine adjuvant according to claim 36, said bacterium is a Gram negative or a Gram positive.

42. (Previously Presented) The vaccine adjuvant according to claim 41, said Gram negative bacterium is one of *Neissera*, *Haemophilus*, *Salmonella*, *Vibrio*, *Pseudomonas* or *Shigella* genus.

43. (Previously Presented) The vaccine adjuvant according to claim 41, said Gram positive bacterium is one of the *Streptococcus* or *Staphylococcus* genus.

44. (Previously Presented) The vaccine adjuvant according to claim 36, said live organism is a protozoan from the *Leishmania* genus.

45. (Previously Presented) The vaccine adjuvant according to claim 36, the outer membrane vesicles comprise a tumor cell vesicles.

46. (Previously Presented) A method for obtaining cochlear structures from vesicles found in the outer membrane of live organisms, comprising the following steps:

(a) preparing from outer membrane vesicles of live organisms selected from a bacterial, protozoan and animal cell organism, of a solution with a total protein concentration between 3 and 6 mg/mL, and adding a non-ionic detergent in a concentration 10 times that of the proteins;

(b) filtering through a membrane with a pore size of 0.2 µm, with the aim of sterilizing and eliminating vesicle aggregates;

- (c) executing a rotational dialysis or a tangential filtration against a solution containing concentrations of a multivalent ion, particularly  $\text{Ca}^{2+}$ ,  $\text{Zn}^{2+}$ , or  $\text{Mg}^{2+}$ , between 2.5 and 6.5 mM, at conditions buffered at  $\text{pH } 7.4 \pm 0.2$ ; and
- (d) mechanically treating the resultant cochlear structures to homogenize the size of the particles.

47. (Previously Presented) The vaccine composition according to claim 1, wherein the composition is administrable mucosally, parenterally, or through a combination of both methods.

48. (Previously Presented) The vaccine composition according to claim 26, wherein the composition is administrable mucosally, parenterally, or through a combination of both methods.

49. (Previously Presented) The adjuvant according to claim 16, wherein the composition is administrable mucosally, parenterally, or through a combination of both methods.

50. (Previously Presented) The adjuvant according to claim 36, wherein the composition is administrable mucosally, parenterally, or through a combination of both methods.

51. (Previously Presented) The vaccine composition of claim 1, further comprising at least one or more antigens.
52. (Previously Presented) The vaccine composition of claim 51, further comprising an excipient.
53. (Previously Presented) The method of claim 46, further comprising adding antigens or pathogen associated molecular pattern to the solution.
54. (Previously Presented) The method of claim 53, following step (a) homogenizing at 0.2 to 2.7 µg for each 3 to 9 µg of protein for the antigens and from 1 to 30% of the protein concentration pathogen associated molecular pattern.
55. (Previously Presented) The method of claim 46, wherein the mechanical treating comprises sonication in a water bath at a temperature between 15°C and 25°C for a period of about 45 minutes.
56. (Cancelled)
57. (Previously Presented) The vaccine composition of claim 26, further comprising at least one or more antigens.

58. (Previously Presented) The vaccine composition of claim 57, further comprising an excipient.